CDCamelia Dascălu

Camelia Dascălu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camelia Dascălu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study

    by Dan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, Camelia Dascălu, Helene Speyer, Cristina Dobre, Ohad Green, Romeo Petru Dobrin, Michael Davidson, Jonathan Rabinowitz, et al.

    Background: Negative symptoms (NS) such as anhedonia (reduced pleasure), avolition (reduced motivation), asociality (social withdrawal), blunted affect (diminished emotional expression), and alogia (poverty of speech) are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. Current medication primarily targets positive or affective symptoms, leaving NS neurobiology unaddressed. A critical research gap exists in understanding whether these symptoms share a common biological architecture across different diagnoses or whether they emerge from distinct pathological pathways. Objective: This observational, single-center study aims to characterize NS across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles and the aim of determining whether particular NS consistently occupy central positions across disorders or centrality patterns differ by diagnosis. By linking these symptom profiles to underlying neurocognitive, electrophysiological, and genetic markers, the study seeks to disentangle shared versus disorder-specific mechanisms. Methods: In total, 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Over a 4-day schedule, participants will undergo clinical (Brief Negative Symptom Scale, Positive and Negative Syndrome Scale, Hamilton Depression Rating Scale, Personal and Social Performance Scale, Udvalg for Kliniske Undersøgelser Side Effect Rating Scale, and Barnes Akathisia Rating Scale), neurocognitive (Brief Assessment of Cognition in Schizophrenia, and Temporal Experience of Pleasure Scale), and biological (resting-state electroencephalography and blood sampling for polygenic risk score) assessments. Network analysis will compute symptom centrality to determine if avolition acts as a transdiagnostic hub. Structural equation modeling will link network profiles to neurophysiological and genetic data. This methodology is designed to identify convergent biological markers, clarify avolition’s role in symptom heterogeneity, and refine understanding of NS as multidimensional phenomena beyond traditional diagnostic boundaries. Results: The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on May 8, 2024, and updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. By March 2026, the study had enrolled 286 participants. Data quality control and preliminary analyses are performed concurrently with data collection. Final statistical analyses and dissemination of results are planned following completion of the recruitment phase. Conclusions: This study will provide critical insights into the characterization and underlying mechanisms of NS across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of NS. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illnesses and related conditions.

  • Open Access

    Smart Drug-Delivery Approaches for Enhanced Management of Comorbid Conditions in Alzheimer’s Disease

    by Gabriela-Dumitrita Stanciu, Ivona Costachescu, Camelia Dascalu, Bogdan-Ionel Tamba

    Alzheimer’s disease (AD) remains a major unmet medical challenge due to its complex pathology, high interpatient heterogeneity and frequent association with systemic comorbidities. Conventional pharmacotherapy is limited by poor blood–brain barrier permeability, off-target effects and reduced efficacy in polymedicated elderly populations. Smart drug-delivery systems (DDS), particularly nanotechnology-based platforms, have emerged as promising strategies to enhance brain targeting, optimize controlled drug release and mitigate systemic toxicity. This review examines recent advances in intelligent DDS for AD, with a focus on nanocarriers designed to modulate amyloid aggregation, neuroinflammation, oxidative stress and cholinergic dysfunction. Special attention is given to the impact of the most common comorbid conditions on DDS pharmacokinetics, safety and clinical performance. Furthermore, the challenges associated with clinical translation, such as long-term safety, immunogenicity, manufacturing scalability and regulatory harmonization, are critically discussed. In this context, versatile controlled release platforms that integrate rational design, predictive modeling and Quality by Design-driven manufacturing are highlighted as key enablers of translational success. By bridging intelligent formulation design with scalable production and regulatory readiness, advanced controlled release systems offer a pathway toward precision and patient-centered therapies. Such platforms hold significant potential to accelerate the safe integration of smart DDS into Alzheimer’s disease management and broader neurotherapeutic applications.


  • Open Access

    Modelling Negative Symptom Domains Neurobiology: Protocol for an Observational Transdiagnostic, Translational Study (Preprint)

    by Dan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, Camelia Dascălu, Helene Speyer, Cristina Dobre, Ohad Green, Romeo Petru Dobrin, Michael Davidson, Jonathan Rabinowitz, et al.

    BACKGROUND Negative symptoms (NS) such as anhedonia, avolition, asociality, blunted affect and alogia are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. OBJECTIVE This protocol describes the design of an observational, single-center study aimed at characterizing negative symptoms across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles. METHODS An observational study (involving no invasive procedures or drug administration other than a routine blood draw) has been designed to examine negative symptoms across psychiatric disorders. A total of 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Consenting inpatients and outpatients will complete a battery of non-invasive behavioral and cognitive assessments, undergo electroencephalogram (EEG) recording, and provide blood samples for the assessment of polygenic risk scores. RESULTS The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on August 5, 2024, and subsequently updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. Data quality control and preliminary analyses are performed concurrently with data collection, while final statistical analyses and dissemination of results are planned following completion of the recruitment phase. CONCLUSIONS This study will provide critical insights into the characterization and underlying mechanisms of negative symptoms across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of negative symptoms. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illness and related conditions.